Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Chugai to File Flurry of Applications in 2017 for New Drugs and Indications Including Emicizumab
February 3, 2017
- Chugai to Mull Authorized Biosimilars for 3 Key Cancer Meds on “Case-by-Case Basis”
February 2, 2017
- Takeda’s R&D Organization Rejig Making Steady Headway as a Whole
February 2, 2017
- New Firm for Nesp Biosimilar Will Broaden Options: Kyowa Kirin President
February 2, 2017
- EA Pharma Seeks Japan Approval of Constipation Med
February 2, 2017
- Chugai Logs Positive Sales in Japan, but Earnings Falter
February 2, 2017
- Gilead to Introduce Blister-Pack Harvoni by Early March
February 2, 2017
- Over 80% of 5-Year-Olds Eligible for Supplemental Dose of Pneumococcal Vaccine: Pfizer Survey
February 2, 2017
- Daiichi Sankyo Taps EVP Manabe as Next President
February 1, 2017
- KHK7580 Non-Inferior to Regpara in Japan Study: Kyowa Kirin
February 1, 2017
- Kyowa Kirin Sets Up New Firm for Nesp Authorized Biosimilar
February 1, 2017
- Daiichi Sankyo Sees High Odds of Success for CAR T-Cell Development: Exec
February 1, 2017
- Kyowa Kirin’s 2016 Sales, Profits Slip on Stronger Yen, Higher R&D Costs
February 1, 2017
- Kyowa Kirin, NCC to Collaborate on Cancer Meds, Biomarkers
February 1, 2017
- Takeda Obtains Japan Rights to Exelixis’ Cancer Drug
February 1, 2017
- Astellas Gets Rights to US Biotech’s Ruptured Eardrum Med
February 1, 2017
- Major Products Face Impending Listing of Generics, though Patents Remain for Some
February 1, 2017
- Biogen to Keep Its Focus on High Unmet Needs, Win-Win Partnerships: CEO
January 31, 2017
- Latuda OK’ed in US for Adolescent Schizophrenia
January 31, 2017
- Mochida Filed Enbrel Biosimilar in Japan in October-December
January 31, 2017
ページ
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…